Literature DB >> 21158720

Silica nanoparticles as promising drug/gene delivery carriers and fluorescent nano-probes: recent advances.

Yiyao Liu1, Changchun Lou, Hong Yang, Mengran Shi, Hirokazu Miyoshi.   

Abstract

The application of nanotechnology to biomedical research is expected to have a major impact leading to the development of new types of diagnostic and therapeutic tools. One focus in nanobiotechnology is to develop safe and efficient drug/gene delivery vehicles. Research into the rational delivery and targeting of pharmaceutical, therapeutic and diagnostic agents is at the forefront of projects in nanomedicine. Silica, as a major and natural component of sand and glass, is a versatile material due to the variety of available chemical and physical modifications that are available, and recently have been widely applied in nanobiotechnology as drug/gene carriers or fluorescent nano-probes. The goal of this brief review is to illustrate selected examples of various functionalized silica nanoparticles as drug/gene delivery systems that have been applied to the arenas of human disease therapy or detection (molecular and cellular imaging).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21158720     DOI: 10.2174/156800911794328411

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  13 in total

1.  Transcriptional responses of human aortic endothelial cells to nanoconstructs used in biomedical applications.

Authors:  Philip J Moos; Matthew Honeggar; Alexander Malugin; Heather Herd; Giridhar Thiagarajan; Hamidreza Ghandehari
Journal:  Mol Pharm       Date:  2013-07-10       Impact factor: 4.939

Review 2.  Luminescent silica nanoparticles for cancer diagnosis.

Authors:  W Arap; R Pasqualini; M Montalti; L Petrizza; L Prodi; E Rampazzo; N Zaccheroni; S Marchiò
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

3.  Formulation design facilitates magnetic nanoparticle delivery to diseased cells and tissues.

Authors:  Dhirender Singh; JoEllyn M McMillan; Xin-Ming Liu; Hemant M Vishwasrao; Alexander V Kabanov; Marina Sokolsky-Papkov; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2014-03-19       Impact factor: 5.307

4.  Interactions of silica nanoparticles with lung epithelial cells and the association to flotillins.

Authors:  Jennifer Kasper; Maria I Hermanns; Christoph Bantz; Olga Koshkina; Thomas Lang; Michael Maskos; Christine Pohl; Ronald E Unger; C James Kirkpatrick
Journal:  Arch Toxicol       Date:  2012-06-06       Impact factor: 5.153

5.  Development of manganese-based nanoparticles as contrast probes for magnetic resonance imaging.

Authors:  Zipeng Zhen; Jin Xie
Journal:  Theranostics       Date:  2012-01-01       Impact factor: 11.556

Review 6.  Integrative nanomedicine: treating cancer with nanoscale natural products.

Authors:  Iris R Bell; Barbara Sarter; Mary Koithan; Prasanta Banerji; Pratip Banerji; Shamini Jain; John Ives
Journal:  Glob Adv Health Med       Date:  2014-01

7.  Biocompatibility of cerium dioxide and silicon dioxide nanoparticles with endothelial cells.

Authors:  Claudia Strobel; Martin Förster; Ingrid Hilger
Journal:  Beilstein J Nanotechnol       Date:  2014-10-17       Impact factor: 3.649

8.  VCAM-1-targeted core/shell nanoparticles for selective adhesion and delivery to endothelial cells with lipopolysaccharide-induced inflammation under shear flow and cellular magnetic resonance imaging in vitro.

Authors:  Hong Yang; Fenglong Zhao; Ying Li; Mingming Xu; Li Li; Chunhui Wu; Hirokazu Miyoshi; Yiyao Liu
Journal:  Int J Nanomedicine       Date:  2013-05-13

9.  A model for homeopathic remedy effects: low dose nanoparticles, allostatic cross-adaptation, and time-dependent sensitization in a complex adaptive system.

Authors:  Iris R Bell; Mary Koithan
Journal:  BMC Complement Altern Med       Date:  2012-10-22       Impact factor: 3.659

10.  Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity.

Authors:  Claire Vanpouille-Box; François Hindré
Journal:  Front Oncol       Date:  2012-10-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.